The National Institutes of Health Renews License With Bioalma in Multi-Year Deal
Primary U.S. Federal Agency for Conducting and Supporting Medical Research to Use Text Mining Technology for Human Salivary Proteome Project
| Source: Bioalma
MADRID, SPAIN--(Marketwire - May 18, 2009) - Bioalma
today announced that the National Institutes
of Health (NIH) has licensed AlmaKnowledgeServer 2
(AKS2) software, the company's informatics system which contains powerful
tools to search, analyze, and visualize all types of information extracted
from biomedical literature. AKS2 is a subscription-based system, and is the
technology that is the basis for Bioalma's free biomedical search tool --
novo|seek.
The Center for Information Technology (CIT) at the NIH has expanded its
licenses of AKS2 by more than 25 percent to ensure that researchers
involved in the human salivary proteome project can utilize the solution as
the annotation platform for the project -- a project with a long-term goal
of supporting the discovery of saliva-based diagnostic tests. Saliva-based
tests hope to provide new "non-invasive" diagnostic methods that can be
performed for little cost in a doctor's office or at a patient's home.
"Being selected yet again by the NIH -- the go-to resource for biomedical
research in the US -- is a proof point to the powerful capabilities behind
our text mining technology -- within both AKS2 and novo|seek," said Ramon Alonso-Allende, director
of marketing and business development, Bioalma. "Our overarching goal is to
put the power of information into the hands of researchers, medical
students, doctors, and librarians, and we continue to add functionality and
expanded resources to our family of biomedical search tools to solve that
ever-increasing problem of mining overwhelming amounts of scientific
literature."
Bioalma will be exhibiting novo|seek -- a powerful alternative to
traditional information retrieval systems aimed at a variety of audiences
within the biomedical community -- at the Bio International Convention this
week at booth #1405/M06.
Tags/keywords: biomedical research, National Institutes of Health, NIH,
research, novo|seek, AKS2
Supporting Resources:
To download the Bioalma corporate backgrounder, please visit: www.novoseek.com/info/ns_backgrounder.html
For information on AKS2: http://www.bioalma.com/aks2/index.php
For more information on novo|seek, visit:
blog: http://blog.novoseek.com/
Twitter feed: http://twitter.com/novoseek/
Facebook group: http://www.facebook.com/pages/novoseek/101834395337
LinkedIn group: http://www.linkedin.com/groups?gid=1699237&trk=hb_side_g
About novo|seek
Novo|seek is a dynamic information extraction system for searching the
published knowledge in biomedical literature.
Novo|seek indexes the biomedical literature with text mining technology
built by Bioalma that identifies key biomedical terms taking into account
external available data and contextual term information. As a result of
this indexing technology, novo|seek retrieves every document where a term
is mentioned no matter the synonym used and discards those documents where
the term is used with an unwanted meaning.
About Bioalma
Located in Madrid, Spain, Bioalma is an IT company specialized in the
research and development of biomedical software.
Bioalma was founded in 2000 as a spin-off of a bioinformatics group in the
National Center of Biotechnology and a privately-held company, as part of
the Bionostra group. Bioalma prides itself on an elite team of well-known,
internationally-leading scientists as part of its scientific committee and
has successfully marketed its technology to different research
institutions, universities, pharmaceutical and biotech companies, including
National Institutes of Health, Universidad Nacional Autonoma de Mexico,
Roche and Althea Technologies.
Bioalma is a privately-owned company, part of the Bionostra group. The
Bionostra Group is composed of four companies that share the common
objective of being leaders in the biotechnology and bioinformatics sectors.
Its main activity is scientific research focused on the development of new
technologies, products and biotechnology services within the field of human
health. Bionostra Group is composed of Bioalma, ChimeraPharma, Bionostra
and Microbionta.